CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53

CD4+ T 细胞淋巴瘤携带嵌合抗原受体整合于 TP53

阅读：1
作者：Perica,Karlo,Jain,Nayan,Scordo,Michael,Patel,Ruchi,Eren,Ozgur Can,Patel,Utsav,Gundem,Gunes,Domenico,Dylan,Mitra,Sneha,Socci,Nicholas D,Everett,John K,Roche,Aoife M,Petrichenko,Angelina,Shah,Gunjan L,Arcila,Maria E,Borsu,Laetitia,Park,Jae H,Horwitz,Steven M,Giralt,Sergio A,Dogan,Ahmet,Leslie,Christina,Papaemmanuil,Elli,Bushman,Frederic D,Usmani,Saad Z,Sadelain,Michel,Mailankody,Sham
期刊：New England Journal of Medicine影响因子：78.500
时间：2025起止号：2025 Feb 6;392(6):577-583
doi：10.1056/NEJMoa2411507

Abstract

Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case of a T-cell lymphoma harboring a lentiviral integration in a known tumor suppressor, TP53, which developed in a patient with multiple myeloma after B-cell maturation antigen (BCMA) CAR T-cell therapy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用；引用内容仅为补充信息，不代表本站立场。

2、若认为本页面引用内容涉及侵权，请及时与本站联系，我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容，需注明“来源：[生知库]”并获得授权；使用引用内容的，需自行联系原作者获得许可。

4、投稿及合作请联系：info@biocloudy.com。